Project Grant R01HL175874
Award Date 8/18/25
Completion Date 5/31/29
Dollars Obligated $666K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Virginia, USA
Similar Awards
- This Project Grant award for $440,000.00, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research at the University of Texas Medical Branch at Galveston to determine the function and mechanism of the long non-coding RNA CHAST in Trypanosoma cruzi infection and dissemination, which causes Chagas disease. The research aims to investigate how T. cruzi deregulates the CHAST-PLEKHM1 pathway...
- The University of Virginia (UVA) received a $800,679 Project Grant award on September 15, 2025 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to conduct research on the pathogenesis of chronic obstructive pulmonary disease (COPD) using metabolomics and genomics data. The key objectives are to develop an enhanced analytical tool, termed MetaboXcan, to integrate GWAS and metabolomics data to gain new insights into the molecular mechanisms...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $449,408 Project Grant under CFDA 93.855 - Allergy and Infectious Diseases Research to Duke University to develop diagnostic antibodies for acute and chronic Chagas disease. The funding will support the generation of a panel of antibodies capable of detecting Trypanosoma cruzi, the parasite that causes Chagas disease, in blood samples. This work aims to address the lack of effective rapid diagnostic tests for Chagas...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $601,169 Project Grant under CFDA 93.837 - Cardiovascular Diseases Research to the Rector & Visitors of the University of Virginia. The grant aims to improve understanding of the molecular basis for the progression of myeloproliferative neoplasms, a group of blood cancers, induced by the JAK2V617F mutation. Key objectives include identifying the tumor-suppressor gene PTPN1 as a potential target, examining its role in enhancing...
- This $726,452 Project Grant was awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant aims to define the multi-scale intra- and inter-cellular signaling networks mediating TRPC6-dependent cardiac fibrosis. The researchers at the University of Virginia will leverage computational methods and models to map pathways from protein interactions into the fibroblast intracellular-intercellular signaling network, in...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), supports the development of a lesion-targeted nanotherapeutic to address vascular smooth muscle cell (VSMC) dysfunction and mitigate neointimal hyperplasia (NIH), which is a significant issue arising from vascular damage during interventions. The project aims to integrate in vitro transcribed CARMN RNA (a long non-coding RNA critical...
- This $720,676 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to develop a novel therapeutic strategy using ultrasound-targeted microbubble cavitation (UTMC) to deliver nitro-fatty acids (NFAs) to the myocardium following a myocardial infarction. The overarching goal is to mitigate microvascular obstruction and myocardial fibrosis, two major complications of myocardial infarction that lead to...
- This Project Grant award, in the amount of $791,485.00, was provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The funding supports research by the University of Pittsburgh to develop an ultrasound-based approach for the targeted delivery of microRNA-92a inhibitors to treat adverse left ventricular remodeling following acute myocardial infarction. The project aims to advance the clinical translation of this...
- This $323,000 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research by the University of Virginia to investigate the role of glucose-6-phosphate dehydrogenase (G6PD) deficiency in the development of atherosclerosis. The researchers will utilize a novel humanized mouse model to assess how G6PD deficiency impacts the production of protective antibodies that inhibit inflammation and atherosclerosis progression. The...
- The federal Project Grant award of $767,077 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) seeks to validate and extend a platform technology for the delivery of protein-based thrombolytic drugs. The bioengineering strategy employs the designed assembly of endogenous biomolecules, including thrombolytic enzymes and vitamin B12, to create a biocompatible drug delivery platform that leverages the circulatory system as a natural drug depot and...